Philips enters into collaboration with Janssen to develop new handheld blood test to support care of patients with neuropsychiatric disorders

March 25, 2015

Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it has entered into a multi-year development agreement with Janssen Pharmaceutica N.V.
(Janssen). The collaboration aims to develop a new handheld blood test to provide doctors with a novel tool to improve the care of patients with neuropsychiatric disorders.


The collaboration unites Philips’ expertise in point-of-care testing and monitoring applications for the hospital and the home, with Janssen’s strength in discovering and developing innovative solutions to treat brain disorders. Philips will be responsible for the development and manufacturing of the handheld test. The test will be based on Philips’ Minicare system, which is currently under development. Janssen will be responsible for the clinical studies to validate the test, as well as the commercialization of the final product.


“Our technology can play an important role in the management of chronic diseases in the hospital and the home,” said Frans van Houten, CEO Royal Philips. “Better care for patients with neuropsychiatric disorders is a key driver to improve patient outcomes and lower healthcare costs. The collaboration with Janssen is a great example of our open innovation business model, combining their strength in neuroscience with the biosensor technology in our Minicare I-20 platform.”


Mr. Van Houten added: “Going forward, I firmly believe that the Minicare system consisting of the analyzer and application-specific cartridges and software, can be tailored to a wide range of other pharmaceuticals.”


The blood test will be based on Philips’ Minicare I-20 system for immunoassays, which consists of a handheld analyzer, dedicated software and a single use, disposable cartridge containing the application specific test.  Based on Philips’ proprietary biosensor technology, the Minicare I -20 system is being developed to detect multiple target molecules at low concentrations within the same blood sample and to show the results on the analyzer display within minutes. 


The Minicare activities are part of Philips’ Handheld Diagnostics business that has its headquarters and manufacturing lines at the High Tech Campus in Eindhoven, the Netherlands. The business will be expanding its production capacity in light of the new partnership.

For further information, please contact:

Steve Klink
Philips Group Communications
Tel.: +31 6 1088 8824


Hans Driessen
Philips Handheld Diagnostics
Tel.: +31 6 10610417


About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 105,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at


Forward-looking statements

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.